Page 8 - Authorization Application News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Home / Top News / Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sickle Cell Disease Patients SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) — Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announ...

(1) In this collaboration Almirall will commercialize Wynzora Cream for treatment of plaque psoriasis in Europe and MC2 Therapeutics will be responsible for manufacturing and supply. MC2 Therapeutics and Almirall partner to make Wynzora Cream a leading topical product for Plaque Psoriasis in Europe In a large European based Phase 3 clinical trial (n=490), Wynzora Cream has demonstrated substantial efficacy with a PGA treatment success of 51% and beneficial treatment convenience 1 Cream has been filed and approval is expected this year Almirall S.A. (BME: ALM), a global biopharmaceutica...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal ... Myovant Sciences, Inc.February 11, 2021 GMT ORGOVYX™ (relugolix) approved by the  U.S. Food and Drug Administration  (FDA) in December 2020 as the first and only oral GnRH receptor antagonist for adult patients with advanced prostate cancer; ORGOVYX launched in the U.S. in early January 2021 Announced collaboration with Pfizer in December 2020 to jointly develop and commercialize relugolix in onco...

Global Blood Therapeutics, Inc.: European Medicines Agency Accepts GBT's Marketing Authorization Application (MAA) for Oxbryta (voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Disease (voxelotor) Tablets Oxbryta (voxelotor) is an oral, once-daily therapy for patients with sickle cell disease (SCD). Oxbryta works by increasing hemoglobin's affinity for oxygen. Since oxygenated sickle hemoglobin does not polymerize, GBT believes Oxbryta blocks polymerization and the resultant sickling and destruction of red blood cells, which are primary pathologies faced by every single person...

Published: Jan 27, 2021 SOUTH SAN FRANCISCO, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics , Inc. (GBT) (NASDAQ: GBT) today announced that the European Medicines Agency (EMA) has completed the validation of GBT’s Marketing Authorization Application (MAA) for Oxbryta ® (voxelotor) tablets and started its standard review process. GBT is seeking full marketing approval from the EMA for Oxbryta to treat hemolytic anemia in patients with sickle cell disease (SCD) who are 12 years of age and older. A first-in-class oral, once-daily therapy, Oxbryta directly inhibits hem...